Clinical Evaluation of Xiaoqinglong Decoction for Acute Exacerbation of Chronic Obstructive Pulmonary Disease--A Systematic Review / 世界科学技术-中医药现代化

ABSTRACT

This study was aimed to assess the clinical evaluation of Xiaoqinglong decoction for acute exacerbation of chronic obstructive pulmonary disease (COPD). Literatures published before August 3rd, 2012 were searched in the database of CNKI, VIP, CBM and Wanfang Data to identify the randomized controlled trials (RCTs) and quasi-RCTs about Xiaoqinglong decoction for acute exacerbation of COPD in China. Literatures were screened ac-cording to the inclusive and exclusive criteria by two reviewers independently. And the methodology quality was evaluated after abstracting the data. Then, the RevMan 5.0 software was used for meta-analysis. Seventeen RCTs were included. Among 1173 patients, there were 608 cases in the clinical trial group and 565 in the control group. The meta-analysis showed that compared with western medicine (WM), the clinical effect of Xiaoqinglong decoction plus WM was significantly better [MD = 3.91, 95%CI (2.50, 6.12), P < 0.01]. The invasive ventilation plus Xiaoqinglong decoction was better than the invasive ventilation [MD = 3.48, 95%CI (1.45, 8.32), P =0.01]. The blood gas analysis showed that compared with WM, the PaO2 in the Xiaoqinglong decoction plus WM was significantly better [MD = 7.55, 95%CI (1.41, 13.68), P = 0.05]. There was statistical significance in PaCO2 of Xiaoqinglong decoction plus WM [MD = -7.11, 95%CI (-9.89, -4.33), P < 0.01]. Compared to the invasive ventilation, there was statistical significance in the invasive ventilation plus Xiaoqinglong decoction [MD = -6.66, 95%CI (-8.79, -4.54), P < 0.01]. For FEV1, compared with WM, Xiaoqinglong decoction plus WM was signifi-cantly better [MD = 6.97, 95%CI (3.60, 10.34), P < 0.01]. It was concluded that Xiaoqinglong decoction com-bined with WM methods can improve clinical efficacy of acute exacerbation of COPD in order to increase the clinical efficacy on a certain level.